Cutaneous Oncology News

The FDA has proposed revisions to the marketing conditions for over-the-counter sunscreen products in order to improve safety and efficacy, according to a press release.

Frailty and comorbidities were some of the patient-related factors that drove patients to choose a watchful waiting approach to basal cell carcinoma, according to a study.

The FDA granted priority review to relatlimab and nivolumab for treatment of unresectable or metastatic melanoma.

Patients with resected stage IIB or stage IIC melanoma who received adjuvant pembrolizumab demonstrated a 35% reduction in risk for disease recurrence or death, according to results of the randomized phase 3 KEYNOTE-716 study.

Cristina Puig-Saus, PhD, and Daniel S. Shin, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center received a $1 million award from the U.S. Department of Defense for research into novel cell therapies for rare melanomas.

Mohs micrographic surgery showed continued efficacy in preventing local recurrence and progression in high-risk cutaneous squamous cell carcinoma, according to a study.

An expert panel has developed recommendations on best practices for managing clinically relevant immune-related adverse events associated with immune checkpoint inhibitor treatment.

Patients treated with Mohs micrographic surgery for nasal skin cancers experienced significant quality of life improvements after reconstruction, according to a study.

CPT codes rather than ICD codes may be a more effective proxy to determine the actual number of skin cancers experienced by an individual patient, according to a study.

Photodynamic therapy with aminolevulinate and imiquimod are among the treatments with good long-term efficacy for actinic keratosis, according to an investigation published in JAMA Dermatology.